Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
Profit before tax in Q4 FY26 stood at Rs 51.70 crore, up by 80.71% from Rs 28.61 crore in Q4 FY25.
On a full-year basis, the company's consolidated net profit jumped 30.69% to Rs 101.43 crore on a 7.75% rise in net sales to Rs 772.77 crore in FY26 over FY25.
Mitesh Dave, Group CEO, said, 'FY2026 represents a pivotal inflection point in Krsnaa Diagnostics' growth journey, marked not only by strong headline financial performance but more significantly by the accelerated emergence of our retail diagnostics vertical, Krsnaa Retail, as a structurally important and independently scalable growth engine for the group.
Within just twelve months of focused scaling, our retail vertical delivered an 8 times jump in revenue and a 7 times surge in touchpoints, expanding to 3,500 locations across 5 states, a pace of growth that firmly establishes Krsnaa Retail as one of the country's most formidable retail diagnostics growth stories. As we enter FY2027, we remain focused on disciplined execution, transparency, and strong governance standards while continuing to uphold the trust placed in us by our investors, partners, and patients.
The company has recommended a final dividend of Rs 2 per equity share of face value Rs 5 each (40% of face value) for FY26, subject to shareholders' approval at the ensuing AGM.
Krsnaa Diagnostics is an integrated diagnostics service provider in India, offering technology-enabled diagnostic services including radiology, pathology, tele-radiology, and clinical laboratory services to public and private healthcare institutions across the country.
Shares of Krsnaa Diagnostics shed 0.27% to Rs 553.65 on the BSE.
Powered by Capital Market - Live News